Brief: Hansa Biopharma Q1 Loss For Period Widens To SEK 138.4 Mln

Hansa Biopharma AB

21/04/2022 07:19

April 21 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * HANSA BIOPHARMA INTERIM REPORT JANUARY - MARCH 2022
    * SOLID SALES GROWTH IN Q1 WITH SEK 24.2M IN PRODUCT SALES;
    * Q1 TOTAL REVENUE AMOUNTED TO SEK 30.3M.
    * Q1 LOSS FOR PERIOD SEK 138.4 MILLION VERSUS SEK 103.9
MILLION
YEAR AGO
    * WITH RESPECT TO OUR GBS PROGRAM, WE HAVE SEEN HOW IMPACT
OF
COVID-19 PANDEMIC AND EMERGENCE OF NEW VARIANTS HAVE NEGATIVELY
AFFECTED ENROLLMENT RATE ACROSS A NUMBER OF TRIAL CENTERS.
    * TO MITIGATE THIS SITUATION WE HAVE RECENTLY IMPLEMENTED
SEVERAL
SIGNIFICANT INITIATIVES TO INCREASE ENROLLMENT RATE AND WE
EXPECT THESE INITIATIVES WILL SUPPORT COMPLETION OF ENROLLMENT
OF GBS PATIENTS IN SECOND HALF OF 2022.

Source text for Eikon:  ID:nWkr5mBRmZ 
Further company coverage:  HNSA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))